All Life Sciences & Technology News
Top stories summarized by our editors
8/18/2017

EpiPen maker Mylan agreed to pay $465 million as part of a final settlement deal with the Justice Department, resolving claims that the firm overcharged the US government by misclassifying the epinephrine auto-injector as a generic product under Medicaid's Drug Rebate Program while it was being marketed and priced as a branded treatment. The settlement, which requires Mylan to reclassify EpiPen and pay rebates applicable to its new classification effective April 1, was criticized by several lawmakers who believe the settlement is too low.

Full Story:
Reuters, The Hill
More Summaries:
Mylan, Mylan, Justice Department, Medicaid
8/18/2017

Pfizer's Besponsa, or inotuzumab ozogamicin, was approved by the FDA as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

8/18/2017

AstraZeneca and Merck received approval from the FDA to expand the indication for Lynparza, or olaparib, to cover use as a maintenance therapy in patients with recurrent ovarian cancer that is responsive to platinum-based chemotherapy. The drug was previously approved as a treatment for women with advanced ovarian cancer who had at least three prior treatments with chemotherapy and were no longer responding to it.

Full Story:
Reuters
More Summaries:
AstraZeneca, Merck, Lynparza, FDA
8/18/2017

Dovonex, a psoriasis ointment, was approved by the UK's Medicines and Healthcare products Regulatory Agency to be sold in pharmacies to treat patients who are at least 18 years old and who have mild to moderate psoriasis. Dovonex was previously available as a prescription-only drug.

Full Story:
PharmaTimes (U.K.)
8/18/2017

Missa Bay issued a voluntary recall of about 1,719 pounds of Cumberland Farms Chicken Caesar Salad because it contains undeclared wheat allergen. The recalled products, which have the establishment number of P18502B and were produced on Aug. 1, were distributed to retail locations in seven Northeastern states.

More Summaries:
Missa Bay, Cumberland Farms
8/18/2017

European regulators gave HeartSciences CE mark approval for its MyoVista high sensitivity electrocardiograph testing device, a technology that uses Continuous Wavelet Transform to measure cardiac energy per heartbeat. The device, which is a combination of traditional 12-lead resting ECG tracings, ECG interpretive analysis and informatics, has also been launched by the company in Europe.

Full Story:
MassDevice (Boston)
More Summaries:
HeartSciences
8/18/2017

The FDA granted Globus Medical clearance to market its robotic guidance and navigation platform, Excelsius GPS, which is designed for use in traditional and minimally invasive orthopedic and neurosurgical procedures. The system facilitates accurate screw placement in spine and orthopedic surgery and can function with intraoperative CT, preoperative CT and fluoroscopic imaging modalities.

Full Story:
Becker's Spine Review
8/18/2017

Preliminary data from a 458-patient study showed Endologix's AFX and AFX2 endografts demonstrated an 84.7% rate of freedom from aneurysm-related complications, compared with 82% for other bifurcated aortic endografts. Further randomization in the study will be stopped by the company based on the number of additional participants needed for proving superiority, while five-year follow-up of current participants will be continued.

More Summaries:
Endologix
8/18/2017

ParaPRO granted RedHill Biopharma exclusive rights to market gastroesophageal reflux disease drug Esomeprazole Strontium Delayed-Release capsules to gastroenterologists in some US territories for at least three years. Under the terms of the deal, RedHill will not need to make upfront or milestone payments but will share revenues with ParaPRO.

8/18/2017

Johnson & Johnson and India's Institute of Microbial Technology, part of the Council of Scientific and Industrial Research, will collaborate on the research and development of new drug compounds for tuberculosis. The partnership will take advantage of J&J's research capabilities and CSIR-IMTECH's microbial technology competence.